Summarized by Masters of Longevity from Longevity Technology.
Voyager is presenting an IV gene therapy and an antibody at CTAD posters.
Key Takeaways
- VY1706 is an intravenous gene therapy meant to lower tau production.
- VY7523 is an antibody targeting the tau protein's C-terminal.
- Clinical posters are descriptive; no efficacy results were reported.